Navigation Links
Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device

REDMOND, Wash., Dec. 19, 2011 /PRNewswire/ -- Cerevast Therapeutics Inc., a privately held medical technology company, announced today that it has received CE mark clearance of its SonoLysis Headframe System, the Clotbust ER™ providing approval to commercialize the product in Europe.


The Clotbust ER™ is a first-in-class ultrasound device for the treatment of ischemic stroke, representing a novel product in an extremely high area of unmet medical need. Designed for rapid deployment in the emergency room setting, the device has been engineered to non-invasively deliver therapeutic ultrasound energy to the region of the occluded vessel in the brain as a treatment for ischemic stroke when used in combination with standard intravenous thrombolytic therapy (tissue plasminogen activator - tPA/Alteplase).

The device contains multiple transducers incorporated into a unique, operator-independent headframe.  The Clotbust ER™ is designed to self-align the transducers based on common landmarks on the skull.  Proprietary software controls the ultrasound parameters, which in turn allows the device to deliver consistent therapeutic levels of ultrasound energy necessary to achieve acoustic streaming and enhanced clot lysis within the occluded vessel of the brain without the need for a trained sonographer or vascular technician.

"Achieving CE mark clearance represents a major accomplishment for Cerevast," said Bradford A. Zakes, Chief Executive Officer. "The Clotbust ER™ significantly reduces the technical challenges associated with the administration of transcranial ultrasound for the treatment of ischemic stroke.  Unlike conventional Doppler instruments that are designed and approved for diagnostic purposes only, the Clotbust ER™ delivers therapeutic ultrasound energy to the region of the occlusion without the need to aim the transducer or hold it in place by hand for extended periods of time.  This represents a major advancement in the emergency room setting where trained sonographers or vascular technicians are not always available."

"It is critically important that treatment be initiated as quickly as possible once a stroke patient presents to the hospital," said Andrei Alexandrov, MD, Professor of Neurology and Director, UAB Comprehensive Stroke Research Center.  "The operator-independent design of the Clotbust ER™ enables safe, fast and reliable amplification of systemic thrombolytic treatment in the emergency room setting.  I look forward to the benefit this product will bring to those patients that suffer the debilitating effects of an ischemic stroke."

About Cerevast Therapeutics, Inc.

Cerevast Therapeutics, Inc. is a medical technology company focused on the development of SonoLysis for the treatment of acute ischemic stroke. Cerevast is a recognized leader in the field of SonoLysis with a dominant intellectual property estate comprising more than 75 issued U.S. patents, 250 foreign issued equivalents and an extensive data package of pre-clinical and clinical studies. The Company is a privately held corporation headquartered in Redmond, WA.

About SonoLysis

SonoLysis is the term used to describe the application of ultrasound energy to disrupt or "lyse" blood clots in the vasculature.  In the setting of acute ischemic stroke, clinical studies have demonstrated that the combination of transcranial ultrasound with conventional thrombolytic therapy results in a significant improvement in both vessel recanalization and rate of complete recovery compared to conventional thrombolytic therapy alone – a major advance in treatment.


SOURCE Cerevast Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
(Date:11/30/2015)... Die MEDTEC Japan 2016, ... Entwicklung und Herstellung medizinischer Geräte, findet ... in Tokyo ... Foto: ... --> ...
(Date:11/30/2015)... India , December 1, 2015 /PRNewswire/ ... --> adds "Endometriosis - Pipeline ... provides an overview on therapeutic pipeline of ... to create effective counter strategies to gain ... identifying new targets and MOAs to produce ...
(Date:11/30/2015)... Nevro Corp. (NYSE: NVRO ), a global ... the treatment of chronic pain, today announced that the Patent ... Trademark Office (USPTO) has denied instituting an inter partes ... patent).  --> --> ... filed two petitions challenging the validity of certain claims of ...
Breaking Medicine Technology:
(Date:11/30/2015)... Minneapolis, MN (PRWEB) , ... November 30, 2015 ... ... launched at . The directory is specialized and only includes chiropractic ... is to find a competent and trustworthy alternative health practitioner when back pain ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... vehicle experience this summer, ushering in a new era of publicly accessible automated ... electric shuttle, will continue to offer guests an up-close look at the shuttle ...
(Date:11/30/2015)... ... 2015 , ... In an effort to provide local families ... Christian Church of Flint, MI, hosted a family-oriented evening themed on “Candy Land”, ... candy dubbed “Candy Mountain”. , A Forever Recovery, a holistic treatment center for ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an effort to ... to access life-saving information provided directly from top experts in mesothelioma, in 2016 ... conferences in three major cities: Houston, San Francisco, and Chicago. , “For ...
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... Foundation kicked off its annual fundraising campaign to raise funds for its research, ... raises approximately 10% of the organization’s annual funding. , The Mesothelioma Applied Research ...
Breaking Medicine News(10 mins):